Phaseline

Targets › TERT

TERT (Telomerase reverse transcriptase): drug programs, companies and trials

4 programs from 4 companies in 6 trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Hematology; next expected readout Feb 2027.

Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. (UniProt, O14746)

Open in Phaseline: the race on TERT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GeronImetelstat sodium
Telomerase reverse transcriptase inhibitor
TERTPhase 3Myelofibrosis; Myelodysplastic SyndromesFeb 2027
Assistance Publique - Hôpitaux de ParisCancer vaccine against TERT and PTPRZ1
Cancer vaccine targeting glioma-associated antigens (TERT and PTPRZ1)
TERT, PTPRZ1Phase 1Newly Diagnosed GlioblastomaMar 2028
Children's Oncology GroupImetelstat
Telomerase reverse transcriptase inhibitor
TERTPhase 1Recurrent Childhood Acute Myeloid LeukemiaMar 2028
Douglas TremblayImetelstat
Telomerase reverse transcriptase inhibitor
TERTPhase 1Relapsed Acute Myeloid LeukemiaJun 2030

Conditions

Myelofibrosis (2) Relapsed Acute Myeloid Leukemia (1) Newly Diagnosed Glioblastoma (1) Myelodysplastic Syndromes (1) Recurrent Childhood Acute Myeloid Leukemia (1)

Modalities

small molecule (2), protein or peptide (1), mixed (1)

Companies

Douglas Tremblay (1) Assistance Publique - Hôpitaux de Paris (1) Geron (1) Children's Oncology Group (1)

Related targets

PTPRZ1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.